07.01.2014
Carl Zeiss Meditec AG DE0005313704
DGAP-Adhoc: Carl Zeiss Meditec strengthens Portfolio of Intraocular Lenses with the Acquisition of Aaren Scientific
Carl Zeiss Meditec AG / Key word(s): Acquisition
07.01.2014 12:47
Dissemination of an Ad hoc announcement according to § 15 WpHG, transmitted
by DGAP - a company of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
---------------------------------------------------------------------------
Carl Zeiss Meditec strengthens Portfolio of Intraocular Lenses with the Acquisition of Aaren Scientific Jena, 7 January 2014: Carl Zeiss Meditec AG (ISIN: DE0005313704) today announces the acquisition of the U.S.-based manufacturer of intraocular lenses (IOLs) Aaren Scientific Inc. (Aaren) headquartered in Ontario, California. The share purchase agreement to acquire 100% of shares in Aaren should be signed today. The transaction is expected to close immediately. Aaren will be incorporated into the strategic business unit Surgical Ophthalmology of Carl Zeiss Meditec AG, complementing existing IOL sites in Berlin, Germany and La Rochelle, France. Aaren has more than two decades worth of experience in manufacturing IOLs and owns rights in CE and FDA approved material for the manufacturing of IOLs. Furthermore, the company has a broad range of highly competitive products. In 2012, Aaren achieved total revenues of approximately USD 20 m, mainly generated outside of the U.S. Aaren currently has 235 employees. The majority of shares in the company had previously been owned by private investment firm James E Sowell Company Inc. of Dallas, Texas, as well as other investors, including the CEO and co-founder of Aaren Scientific, Rick Aguilera, who will stay on board with his management team. The purchase price for 100% of the shares of Aaren Scientific amounts to USD 70 m in cash on a cash free/debt free basis. Insertion of an intraocular lens after cataract surgery is the most commonly performed ophthalmic surgical procedure. While the vast majority of IOLs implanted to treat cataracts are monofocal lenses, Carl Zeiss Meditec has especially shaped the market with its multifocal intraocular lenses. Carl Zeiss Meditec offers cataract surgeons a complete integrated solution to treat cataracts from diagnosis to surgery and aftercare. About 70% of all cataract patients come in contact with a product of Carl Zeiss Meditec. The Strategic Business Unit Surgical Ophthalmology has reported very encouraging growth rates driven by strong demand for innovative IOLs over the last few years.Contact for investors Sebastian Frericks, Director Investor Relations, Carl Zeiss Meditec AG Tel. +49 3641 220-116, E-Mail: [email protected] Press contact Jann Gerrit Ohlendorf, Director Corporate Communications, Carl Zeiss Meditec AG Tel. +49 3641 220-331, E-Mail: [email protected] 07.01.2014 DGAP's Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Media archive at www.dgap-medientreff.de and www.dgap.de --------------------------------------------------------------------------- Language: English Company: Carl Zeiss Meditec AG Göschwitzer Str. 51-52 07745 Jena Germany Phone: +49 (0)3641 220-0 Fax: +49 (0)3641 220-112 E-mail: [email protected],[email protected] Internet: www.meditec.zeiss.de ISIN: DE0005313704 WKN: 531370 Listed: Regulierter Markt in Frankfurt (Prime Standard); Freiverkehr in Berlin, Düsseldorf, Hamburg, Hannover, München, Stuttgart End of Announcement DGAP News-Service ---------------------------------------------------------------------------
|
Weitere Ad-hoc und Unternehmensrelevante Mitteilungen zu
Carl Zeiss Meditec AG ISIN: DE0005313704 können Sie bei EQS abrufen
Medtech , 531370 , AFX , XETR:AFX